Global Autoimmune Collaboration and Licensing Deals Analysis Report and Directory 2023
07 nov. 2023 04h53 HE
|
Research and Markets
Dublin, Nov. 07, 2023 (GLOBE NEWSWIRE) -- The "Autoimmune Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering. The "Autoimmune Collaboration...
Global Claudin 18.2-Targeted Immunotherapy Landscape Analysis Report 2023: Detailed Profiles of 56 Anti-CLDN18.2 Immunotherapy Candidates
22 sept. 2023 04h23 HE
|
Research and Markets
Dublin, Sept. 22, 2023 (GLOBE NEWSWIRE) -- The "Claudin 18.2-Targeted Immunotherapy: A Landscape Analysis of Stakeholders, Drug Modalities, Pipeline and Business Opportunities from An Industry...
Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering
19 sept. 2023 16h05 HE
|
Scinai Immunotherapeutics Ltd.
JERUSALEM, Sept. 19, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing...
Oncology Drugs Global Market Opportunities and Strategies to 2032
25 mai 2023 09h33 HE
|
Research and Markets
Dublin, May 25, 2023 (GLOBE NEWSWIRE) -- The "Oncology Drugs Global Market Opportunities and Strategies to 2032" report has been added to ResearchAndMarkets.com's offering.This report describes and...
Cancer Immunotherapy Global Market to 2032: Rising Cancer Incidence is Expected to Propel the Sector
26 avr. 2023 09h33 HE
|
Research and Markets
Dublin, April 26, 2023 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides strategists,...
Global Autoimmune Partnering 2016-2023: Deal Trends, Players and Financials
03 avr. 2023 05h53 HE
|
Research and Markets
Dublin, April 03, 2023 (GLOBE NEWSWIRE) -- The "Global Autoimmune Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.Global...
BiondVax Announces Closing of $8 Million Underwritten Public Offering
20 déc. 2022 12h42 HE
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Dec. 20, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV)(“Company”), a biotechnology company, which focuses on developing, manufacturing, and...
IBN (InvestorBrandNetwork) Coverage Initiated for BiondVax Pharmaceuticals Ltd.
06 déc. 2022 08h30 HE
|
BiondVax Pharmaceuticals Ltd.
LOS ANGELES, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing...
Global Autoimmune Partnering Deals Report 2022: Disease Deal Trends, Key Players and Top Deal Values
06 déc. 2022 07h08 HE
|
Research and Markets
Dublin, Dec. 06, 2022 (GLOBE NEWSWIRE) -- The "Global Autoimmune Partnering 2015-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.Global...
RIGImmune Announces Acquisition of Antiviral Company Subintro and Concurrent Financing by F-Prime Capital
15 sept. 2022 08h00 HE
|
RIGImmune
FARMINGTON, Conn., Sept. 15, 2022 (GLOBE NEWSWIRE) -- RIGImmune Inc., a biopharmaceutical company developing a new class of RNA immunotherapeutics, today announced the acquisition of Subintro, a...